JP2007512371A5 - - Google Patents

Download PDF

Info

Publication number
JP2007512371A5
JP2007512371A5 JP2006541701A JP2006541701A JP2007512371A5 JP 2007512371 A5 JP2007512371 A5 JP 2007512371A5 JP 2006541701 A JP2006541701 A JP 2006541701A JP 2006541701 A JP2006541701 A JP 2006541701A JP 2007512371 A5 JP2007512371 A5 JP 2007512371A5
Authority
JP
Japan
Prior art keywords
vitamin
analogue
pharmaceutical composition
composition
methylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2006541701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512371A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/039524 external-priority patent/WO2005051396A2/en
Publication of JP2007512371A publication Critical patent/JP2007512371A/ja
Publication of JP2007512371A5 publication Critical patent/JP2007512371A5/ja
Ceased legal-status Critical Current

Links

JP2006541701A 2003-11-25 2004-11-24 ビタミン化合物を用いる体脂肪の減少方法 Ceased JP2007512371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52481303P 2003-11-25 2003-11-25
US52479803P 2003-11-25 2003-11-25
PCT/US2004/039524 WO2005051396A2 (en) 2003-11-25 2004-11-24 Methods for reducing body fat using vitamin d compounds

Publications (2)

Publication Number Publication Date
JP2007512371A JP2007512371A (ja) 2007-05-17
JP2007512371A5 true JP2007512371A5 (cg-RX-API-DMAC7.html) 2008-01-24

Family

ID=41057500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541701A Ceased JP2007512371A (ja) 2003-11-25 2004-11-24 ビタミン化合物を用いる体脂肪の減少方法

Country Status (4)

Country Link
US (1) US7053075B2 (cg-RX-API-DMAC7.html)
EP (1) EP1694333A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007512371A (cg-RX-API-DMAC7.html)
WO (1) WO2005051396A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
KR20050120787A (ko) * 2003-04-10 2005-12-23 위스콘신 얼럼나이 리서어치 화운데이션 2-프로필리덴-19-노르-비타민 d 화합물
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
DE602005020842D1 (de) * 2004-11-22 2010-06-02 Wisconsin Alumni Res Found 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen
US7244719B2 (en) 2004-11-22 2007-07-17 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
CA2597624C (en) * 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
EP1848442B1 (en) * 2005-02-11 2012-04-25 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24epi)-1alpha,25-dihydroxyvitamine-d2
US8945652B2 (en) 2005-11-23 2015-02-03 The Coca-Cola Company High-potency sweetener for weight management and compositions sweetened therewith
US7803789B2 (en) 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
US20070232014A1 (en) * 2006-04-03 2007-10-04 Honeywell International Inc. Method of fabricating a planar MIM capacitor
MX2008012673A (es) * 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-19, 21-dinorvitamina d3 y sus usos.
MX2008012913A (es) * 2006-04-06 2009-03-06 Wisconsin Alumni Res Found 2-metilen-1a,25-dihidroxi-18,19,21-trinorvitamina d3 y sus usos.
US8575136B2 (en) * 2006-04-06 2013-11-05 Wisconsin Alumni Research Foundation 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof
AU2007291005A1 (en) * 2006-04-06 2008-03-06 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2,or 3,2 heterocyclic ring
EP2021320A2 (en) 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
AU2007234717B2 (en) * 2006-04-06 2012-04-19 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
ATE496885T1 (de) * 2006-04-10 2011-02-15 Wisconsin Alumni Res Found 1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor vitamin-d-verbindungen mit einer 1,1- dimethylpropyl-seitenkette
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
US20080153775A1 (en) * 2006-12-21 2008-06-26 Dillard Floyd S Weight reduction program and method
ES3047207T3 (en) * 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
BRPI0907954A2 (pt) * 2008-02-13 2015-08-04 Dsm Ip Assets Bv Tratamento de hipertensão com 25-hidroxivitamina d3
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
WO2011119610A2 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
JP5931845B2 (ja) * 2010-03-23 2016-06-08 ウイスコンシン アラムニ リサーチ ファンデーション 2−メチレン−19−ノル−22−メチル−1α,25−ジヒドロキシビタミンD3のジアステレオマー
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
JP2012016293A (ja) * 2010-07-06 2012-01-26 Nippon Formula Feed Mfg Co Ltd 家禽用飼料
US8420839B1 (en) * 2011-10-05 2013-04-16 Wisconsin Alumni Research Foundation Crystallization of 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0695892B2 (ja) * 1990-01-12 1994-11-30 伊藤忠飼料株式会社 体脂肪の畜積量を減少させる飼料
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 2−位に置換基を有する19−ノル−ビタミンd3 化合物
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6310105B1 (en) * 2000-02-15 2001-10-30 Wisconsin Alumni Research Foundation Carboxyl-modified superabsorbent protein hydrogel
BR0113703A (pt) * 2000-09-08 2003-07-22 Wisconsin Alumni Researcg Foun Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
WO2005027929A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
AU2004273658A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation (Warf) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
NZ545803A (en) * 2003-09-19 2008-03-28 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue

Similar Documents

Publication Publication Date Title
WO2005051396A3 (en) Methods for reducing body fat using vitamin d compounds
JP2001518509A5 (cg-RX-API-DMAC7.html)
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
JP2002522485A5 (cg-RX-API-DMAC7.html)
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
EP2260850A3 (en) A2A receptor antogonists for use in the treatment of movement disorders
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2002516282A5 (cg-RX-API-DMAC7.html)
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
JP2005538190A5 (cg-RX-API-DMAC7.html)
RU2013137645A (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
JP2007509146A5 (cg-RX-API-DMAC7.html)
JP2014508758A5 (cg-RX-API-DMAC7.html)
JP2019514990A5 (cg-RX-API-DMAC7.html)
NO20080244L (no) Doseringsstyring for prasugrel
EP2392322A3 (en) Dosing regimes for trans-clomiphene
ATE464052T1 (de) Neue pharmazeutische verwendungen von staurosporin-derivaten
RU2010107177A (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JP2002540148A5 (cg-RX-API-DMAC7.html)
JP2025098147A5 (cg-RX-API-DMAC7.html)
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
Bellinger et al. Meal patterns in female rats during and after intermittent nicotine administration
JP2008508253A5 (cg-RX-API-DMAC7.html)